Table 1.
Demographic and Clinical Characteristics of the Participants in the Population-Based CARRIERS Analysis.*
| Variable | Case Patients (N = 32,247) | Controls (N = 32,544) |
|---|---|---|
| Demographic characteristic | ||
| Age† | ||
| Mean — yr | 62.07±11.44 | 61.22±11.82 |
| Range — yr | 21.00–94.00 | 21.80–94.30 |
| Distribution — no./total no. (%) | ||
| ≤40 yr | 1,099/31,708 (3.5) | 1,599/32,542 (4.9) |
| 41–50 yr | 4,197/31,708 (13.2) | 4,443/32,542 (13.7) |
| 51–60 yr | 7,999/31,708 (25.2) | 8,580/32,542 (26.4) |
| 61–70 yr | 10,357/31,708 (32.7) | 10,095/32,542 (31.0) |
| >70 yr | 8,056/31,708 (25.4) | 7,825/32,542 (24.0) |
| Race or ethnic group — no./total no. (%)‡ | ||
| Asian | 1,282/32,068 (4.0) | 1,269/32,498 (3.9) |
| Non-Hispanic Black | 3,946/32,068 (12.3) | 4,954/32,498 (15.2) |
| Hispanic | 1,019/32,068 (3.2) | 998/32,498 (3.1) |
| Non-Hispanic White | 25,287/32,068 (78.9) | 24,770/32,498 (76.2) |
| Other | 534/32,068 (1.7) | 507/32,498 (1.6) |
| Participants in included study — no./total no. (%) | ||
| BWHS | 1,437/32,247 (4.5) | 2,896/32,544 (8.9) |
| CPSII | 4,037/32,247 (12.5) | 3,935/32,544 (12.1) |
| CPS3 | 1,537/32,247 (4.8) | 1,729/32,544 (5.3) |
| CTS | 2,226/32,247 (6.9) | 2,134/32,544 (6.6) |
| MCBCS | 4,517/32,247 (14.0) | 3,249/32,544 (10.0) |
| MEC | 3,641/32,247 (11.3) | 3,689/32,544 (11.3) |
| MMHS | 291/32,247 (0.9) | 1,257/32,544 (3.9) |
| NHS | 2,088/32,247 (6.5) | 2,420/32,544 (7.4) |
| NHSII | 935/32,247 (2.9) | 1,391/32,544 (4.3) |
| WCHS | 2,215/32,247 (6.9) | 1,705/32,544 (5.2) |
| WHI | 4,994/32,247 (15.5) | 4,535/32,544 (13.9) |
| WWHS | 4,329/32,247 (13.4) | 3,604/32,544 (11.1) |
| Family history of breast cancer — no./total no. (%)§ | ||
| No | 24,873/31,234 (79.6) | 27,016/31,527 (85.7) |
| Yes | 6,361/31,234 (20.4) | 4,511/31,527 (14.3) |
| Family history of ovarian cancer — no./total no. (%)§ | ||
| No | 27,494/28,534 (96.4) | 28,002/28,949 (96.7) |
| Yes | 1,040/28,534 (3.6) | 947/28,949 (3.3) |
| Clinical characteristic | ||
| Tumor behavior — no./total no. (%) | ||
| In situ | 4,446/31,221 (14.2) | NA |
| Invasive | 26,775/31,221 (85.8) | NA |
| Estrogen-receptor status — no./total no. (%) | ||
| Negative | 3,805/22,233 (17.1) | NA |
| Positive | 18,428/22,233 (82.9) | NA |
| Progesterone-receptor status — no./total no. (%) | ||
| Negative | 6,186/21,643 (28.6) | NA |
| Positive | 15,457/21,643 (71.4) | NA |
| HER2 status — no./total no. (%) | ||
| Negative | 11,077/13,252 (83.6) | NA |
| Positive | 2,175/13,252 (16.4) | NA |
| Triple-negative breast cancer — no./total no. (%) | ||
| No | 11,452/12,915 (88.7) | NA |
| Yes | 1,463/12,915 (11.3) | NA |
Plus-minus values are means ±SD. Percentages may not total 100 because of rounding. The population-based Cancer Risk Estimates Related to Susceptibility (CARRIERS) analysis included data from the Black Women’s Health Study (BWHS), the Cancer Prevention Study II (CPSII), the Cancer Prevention Study 3 (CPS3), the California Teachers’ Study (CTS), the Mayo Clinic Breast Cancer Study (MCBCS), the Multiethnic Cohort Study (MEC), the Mayo Mammography Health Study (MMHS), the Nurses’ Health Study (NHS), the Nurses’ Health Study II (NHSII), the Women’s Circle of Health Study (WCHS), the Women’s Health Initiative (WHI), and the Wisconsin Women’s Health Study (WWHS). NA denotes not applicable and HER2 human epidermal growth factor receptor 2.
Age at the time of breast cancer diagnosis was used for case patients, and age at the time of selection into the study was used for controls. Data on age were missing for 539 case patients and for 2 controls.
Race or ethnic group was reported by the participant.
Family history was restricted to first-degree relatives.